Multiple sclerosis is a chronic, autoimmune disease of demyelinating pathogenesis that is considered one of the most common causes of disability in young adults. There are 2 approaches in the treatment of multiple sclerosis: maintenance therapy and immunoreconstructive approach. Both approaches use disease-modifying drugs. These drugs can cause changes in the immune system by various mechanisms, thus increasing the risk of opportunistic infections and other forms of infectious complications. Progression of multiple sclerosis often leads to central nervous system dysfunction which is manifested by symptoms that may contribute to an increased risk of infections. The damage can lead to the development of bladder dysfunction or dysphagia. These two conditions increase the risk of urinary tract infections and aspiration pneumonia by separate mechanisms. At the time of the SARS – CoV – 2 virus pandemics, the relationship between disease-modifying drugs and the risk of adverse outcomes in those receiving the drug was investigated. It has been found that certain medications do not increase the risk of infection, but only of a poor outcome of infection if someone becomes infected. People with MS require an individual approach during treatment during the pandemic period and pose an additional challenge to the clinician caring for that group of patients. It is important to know the risk of infections, caused by various factors to which people with multiple sclerosis are exposed, in order to provide them with optimal care and protection from the development of infections that can complicate the final outcome of treatment.